Type 1 diabetes
dc.contributor.author | DiMeglio, Linda A. | |
dc.contributor.author | Evans-Molina, Carmella | |
dc.contributor.author | Oram, Richard A. | |
dc.contributor.department | Pediatrics, IU School of Medicine | en_US |
dc.date.accessioned | 2019-09-05T15:48:58Z | |
dc.date.available | 2019-09-05T15:48:58Z | |
dc.date.issued | 2018-06-16 | |
dc.description.abstract | Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the disease, including its genetics, epidemiology, immune and β-cell phenotypes, and disease burden. Interventions to preserve β cells have been tested, and several methods to improve clinical disease management have been assessed. However, wide gaps still exist in our understanding of type 1 diabetes and our ability to standardise clinical care and decrease disease-associated complications and burden. This Seminar gives an overview of the current understanding of the disease and potential future directions for research and care. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Type 1 diabetes. Lancet (London, England), 391(10138), 2449–2462. doi:10.1016/S0140-6736(18)31320-5 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/20795 | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/S0140-6736(18)31320-5 | en_US |
dc.relation.journal | Lancet | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Blood Glucose | en_US |
dc.subject | Diabetes Mellitus, Type 1 | en_US |
dc.subject | Glycated Hemoglobin A | en_US |
dc.subject | Haplotypes | en_US |
dc.subject | Hypoglycemic Agents | en_US |
dc.title | Type 1 diabetes | en_US |
dc.type | Article | en_US |